What’s the current market cap for Eli Lilly stock?

Eli Lilly (LLY) has a market cap of $1T as of May 29, 2026.

What is the P/E ratio for Eli Lilly stock?

The price to earnings (P/E) ratio for Eli Lilly (LLY) stock is 40.03 as of May 29, 2026.

Does Eli Lilly stock pay dividends?

Yes, the Eli Lilly (LLY) stock pays dividends to shareholders. As of May 29, 2026, the dividend rate is $6.23 and the yield is 0.61%. Eli Lilly has a payout ratio of 22.1% on a trailing twelve-month basis.

When is the next Eli Lilly dividend payment date?

The next Eli Lilly (LLY) dividend payment is scheduled for June 10, 2026.

What is the beta indicator for Eli Lilly?

Eli Lilly (LLY) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Eli Lilly stock | $LLY Share Price

About Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Ticker

$LLY

Sector

Health

Primary listing

NYSE

Employees

50,000

Headquarters

Indianapolis, United States

Website

www.lilly.com

Eli Lilly Metrics

BasicAdvanced

$1tn

40.03

$28.15

0.48

$6.23

0.61%

What the Analysts think about Eli Lilly

Analyst ratings (Buy, Hold, Sell) for Eli Lilly stock.

Bulls say / Bears say

Eli Lilly reported Q1 2026 adjusted EPS of $8.55 on $19.8 billion in revenue—a 55.5% year-over-year increase—surpassing consensus and prompting a raise to its full-year profit and revenue guidance. (Reuters)

Surging GLP-1 sales drove performance: Mounjaro generated $8.7 billion and Zepbound $4.2 billion in Q1, each topping street estimates and solidifying Lilly’s leadership in obesity and diabetes treatments. (Reuters)

Lilly’s Phase 3 trial of retatrutide showed patients lost an average of 28.7% of body weight (~71 pounds) at 68 weeks—outperforming Zepbound and reinforcing the company’s next-generation obesity pipeline. (Reuters)

Pricing pressures have intensified as Eli Lilly navigates lower U.S. and international drug prices—including discount agreements with the U.S. government—raising questions over the sustainability of translating strong volume into long-term revenue growth. (Reuters)

Shares dipped after Novo Nordisk’s Wegovy secured FDA approval for metabolic dysfunction-associated steatohepatitis, underscoring escalating competition and potential market share losses for Lilly’s obesity franchise, including Zepbound. (Reuters)

The FDA’s March draft guidance to streamline biosimilar approvals could halve development costs and speed market entry of cheaper biologic competitors, threatening Lilly’s high-spend franchises such as Trulicity and Taltz. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 19 May 2026.

Eli Lilly Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Eli Lilly Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Eli Lilly News

AllArticlesVideos

Lilly's Mounjaro tops other GLP-1s for some type 2 diabetes patients

Reuters·4 hours ago

Lilly's GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans

Market Watch·20 hours ago

CVS brings back coverage for Lilly's obesity drug Zepbound

Reuters·1 day ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.